title: Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor.
abstract: The functions of the first two Kunitz domains of tissue factor pathway inhibitor (TFPI) are well defined as active site-directed inhibitors of factor VIIa and factor Xa. The anticoagulant properties of the third Kunitz domain and C-terminal region were probed using altered forms of TFPI. TFPI-160 contains the first two Kunitz domains. K1K2C contains the first two Kunitz domains and the basic C-terminus. Neither TFPI-160 nor K1K2C contains the third Kunitz domain. In amidolytic assays containing calcium, TFPI-160 is a less potent inhibitor of factor Xa than TFPI. However, addition of the C-terminus in K1K2C nearly restores inhibitory activity to that of TFPI, indicating that the third Kunitz domain is not required for direct inhibition of factor Xa. When compared in assays containing phospholipids and factor Va, K1K2C and TFPI-160 are poor inhibitors compared to TFPI, demonstrating that the third Kunitz domain is required for the full anticoagulant activity of TFPI. TFPI was further characterized in amidolytic assays performed with Gla-domainless factor Xa and in prothrombin activation assays using submicellar concentrations of short-chain phospholipids (C6PS). TFPI and K1K2C are worse inhibitors of Gla-domainless factor Xa, compared to wild-type factor Xa, while TFPI-160 inhibits both forms of factor Xa equally, suggesting a C-terminus/Gla domain interaction. TFPI is a potent inhibitor of thrombin generation by prothrombinase assembled with C6PS, while TFPI-160 and K1K2C are not. Conversely, TFPI does not inhibit prothrombin activation by prothrombinase assembled on a two-dimensional lipid bilayer. Together, the data indicate that the region between Gly-160 and the end of the third Kunitz domain contributes to TFPI function by orienting the second Kunitz domain so that it can bind the active site of phospholipid-associated factor Xa prior to prothrombinase assembly and/or by slowing formation of the prothrombinase complex.
authors.affiliation: Research and Pathology Services, Department of Veterans Affairs, Memphis, Tennessee 38104, USA.
authors.forename: J Marcus
authors.initials: JM
authors.lastname: Lockett
authors.forename: Alan E
authors.initials: AE
authors.lastname: Mast
mesh_terms: D000595:Amino Acid Sequence; D000925:Anticoagulants / Q000737:chemistry* / Q000494:pharmacology; D001665:Binding Sites; D015942:Factor VIIa / Q000037:antagonists & inhibitors; D005170:Factor X / Q000037:antagonists & inhibitors*; D005998:Glycine; D006801:Humans; D007700:Kinetics; D008074:Lipoproteins / Q000737:chemistry*; D008958:Models, Molecular; D008969:Molecular Sequence Data; D017433:Protein Structure, Secondary; D011516:Prothrombin / Q000378:metabolism; D011994:Recombinant Proteins / Q000737:chemistry / Q000494:pharmacology; D013925:Thromboplastin / Q000378:metabolism
chemical_list: D000925:Anticoagulants; D008074:Lipoproteins; D011994:Recombinant Proteins; C051928:lipoprotein-associated coagulation inhibitor; D011516:Prothrombin; D005170:Factor X; D013925:Thromboplastin; D015942:Factor VIIa; D005998:Glycine